RecruitingPhase 1Phase 2NCT06085729
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
Sponsor
M.D. Anderson Cancer Center
Enrollment
30 participants
Start Date
Feb 29, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
Eligibility
Sex: MALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called ADI-PEG 20, a drug called Cabazitaxel, and others for people with prostate cancer. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGADI-PEG 20
Given by Injection
DRUGCabazitaxel
Given by IV (vein)
DRUGCarboplatin
Given by IV (vein)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06085729
Related Trials
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT0685527788 locations
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
NCT060968701 location
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT0654594218 locations
IDOV-Immune for Advanced Solid Tumors
NCT069106575 locations
PSMA PET Combined With MRI for the Detection of PCa
NCT0705221418 locations